Sciessent has announced the results of recent tests with its AgionÒ antimicrobial treatment. According to the company, the treatment achieves 99.99 percent inactivation of SARS-CoV-2, the virus that causes COVID-19, in lab testing of medical textiles. The testing was conducted under ISO 18184 protocols and demonstrated that its effectiveness was maintained even after 20 launderings.
The Agion antimicrobial can be applied to knit or woven medical textiles as a finish, as was tested in this study, or incorporated into the polymer itself for nonwoven textiles in a meltblown process. Paul C. Ford, CEO of Sciessent, called the research “a significant win for manufacturers of FDA-regulated medical textiles treated with Agion.”
“We have conducted numerous studies on the effectiveness of Agion against other coronaviruses but this is the first showing high efficacy against SARS-CoV-2 in washed fabrics,” said Ford. This success “opens the door” for the products potential use in more applications, including N95 masks and other PPE, he added.
Sciessent is a provider of customized antimicrobial solutions based in Massachusetts.